Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages
- 1 December 2005
- journal article
- clinical trial
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 103 (6) , 1000-1009
- https://doi.org/10.3171/jns.2005.103.6.1000
Abstract
Object. To improve the effectiveness of boron neutron capture therapy (BNCT) for malignant gliomas, the authors used epithermal rather than thermal neutrons for deep penetration and two boron compounds—sodium borocaptate (BSH) and boronophenylalanine (BPA)—with different accumulation mechanisms to increase the boron level in tumors while compensating for each other's faults. Methods. Thirteen patients, 10 of whom harbored a glioblastoma multiforme (GBM), one a gliosarcoma, one an anaplastic astrocytoma, and one an anaplastic oligoastrocytoma, were treated using this modified BNCT between January 2002 and December 2003. Postoperatively, neuroimaging revealed that only one patient with a GBM had no lesion enhancement postoperatively. The patients underwent 18F-BPA positron emission tomography, if available, to assess the accumulation and distribution of BPA before neutron radiotherapy. The neutron fluence rate was estimated using the Simulation Environments for Radiotherapy Applications dose-planning system before irradiation. The patients' volume assessments were performed using magnetic resonance (MR) imaging or computerized tomography (CT) scanning. Improvements in the disease as seen on neuroimages were assessed between 2 and 7 days after irradiation to determine the initial effects of BNCT; its maximal effects were also analyzed on serial neuroimages. The mean tumor volume before BNCT was 42.3 cm3. Regardless of the pre-BNCT tumor volume, in every patient harboring an assessable lesion, improvements on MR or CT images were recognized both at the initial assessment (range of volume reduction rate 17.4–71%, mean rate 46.4%) and at follow-up assessments (range of volume reduction rates 30.3–87.6%, mean rate 58.5%). More than 50% of the contrast-enhanced lesions disappeared in eight of the 12 patients during the follow-up period. Conclusions. This modified BNCT produced a good improvement in malignant gliomas, as seen on neuroimages.Keywords
This publication has 16 references indexed in Scilit:
- Histopathological Findings in Autopsied Glioblastoma Patients Treated by Mixed Neutron Beam BNCTJournal of Neuro-Oncology, 2004
- The Early Successful Treatment of Glioblastoma Patients with Modified boron Neutron Capture TherapyJournal of Neuro-Oncology, 2003
- Boron neutron capture therapy for glioblastoma multiforme: clinical studies in SwedenJournal of Neuro-Oncology, 2003
- Age and Radiation Response in Glioblastoma MultiformeNeurosurgery, 2001
- Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood–brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanineInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Boron Neutron-Capture Therapy (BNCT) for Glioblastoma Multiforme (GBM) Using the Epithermal Neutron Beam at the Brookhaven National LaboratoryInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging studyJournal of Neurosurgery, 1997
- Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: Its relation to quiescent cell population and tumor cure in neutron capture therapyInternational Journal of Radiation Oncology*Biology*Physics, 1996
- A HISTORY OF BORON NEUTRON CAPTURE THERAPY OF BRAIN TUMOURSBrain, 1991
- Detection of Nuclear Disintegration in a Photographic EmulsionNature, 1935